New England Journal of Medicine
NEJM is the most influential medical journal. When a cancer drug trial changes how patients are treated, the paper is usually here, often published the same day it is presented at ASCO, ESMO or ASH.
Overview
Weekly general-medicine journal with the highest bar for randomised evidence and the largest share of practice-changing oncology phase 3 trials (IRIS imatinib, KEYNOTE-189, DESTINY-Breast04, CheckMate 067, ZUMA-1 and dozens more in this corpus). Editorials and correspondence often carry the critical reading of a trial. Paywalled, with abstracts free and many trial papers free six months after publication; requires a data-sharing statement for clinical trials under ICMJE rules.
Cabozantinib is approved for previously treated neuroendocrine tumours of any origin and is a standard later-line choice, including for lung carcinoids.
Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).
Lutetium-177 dotatate is a standard treatment for progressive small bowel neuroendocrine tumours after somatostatin analogues, and NETTER-2 has since moved it into first-line use for higher-grade tumours.
An interim PET scan after two cycles guides treatment of advanced Hodgkin lymphoma: drop bleomycin if negative, intensify if positive.
Somatostatin analogues are the standard first-line antiproliferative treatment for grade 1 to 2 gastroenteropancreatic neuroendocrine tumours whether or not they cause a hormone syndrome.
Radium-223 is an option for symptomatic bone-predominant castration-resistant prostate cancer, now less used since lutetium-PSMA, and should not be combined with abiraterone after the ERA 223 fracture signal.
Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.
London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.
Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours.
Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.
Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.
Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.
Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.
One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.
Founder and chair of the APCCC consensus conference that guides advanced prostate cancer management worldwide.
Notes
top- Holds: The practice-changing phase 3 trials, most published simultaneously with ASCO, ESMO and ASH presentations. Access: Paywalled; abstracts free; many trial papers free after 6 months.
Cabozantinib is approved for previously treated neuroendocrine tumours of any origin and is a standard later-line choice, including for lung carcinoids.
Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).
Lutetium-177 dotatate is a standard treatment for progressive small bowel neuroendocrine tumours after somatostatin analogues, and NETTER-2 has since moved it into first-line use for higher-grade tumours.
An interim PET scan after two cycles guides treatment of advanced Hodgkin lymphoma: drop bleomycin if negative, intensify if positive.
Somatostatin analogues are the standard first-line antiproliferative treatment for grade 1 to 2 gastroenteropancreatic neuroendocrine tumours whether or not they cause a hormone syndrome.
Radium-223 is an option for symptomatic bone-predominant castration-resistant prostate cancer, now less used since lutetium-PSMA, and should not be combined with abiraterone after the ERA 223 fracture signal.
Similar pages
not linked directly; found by shared links- IndicationSmall intestinal neuroendocrine tumours
Shares CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours, CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours, NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide.
- IndicationPancreatic neuroendocrine tumours
Shares CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours, CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours.